BioVaxys Technology (BVAXF)
OTHER OTC:BVAXF
BVAXF Stock Chart & Stats
$0.05
<$0.01(0.22%)
At close: 4:00 PM EST
$0.05
<$0.01(0.22%)
Day’s Range― - ―
52-Week Range$0.03 - $0.41
Previous CloseN/A
VolumeN/A
Average Volume (3M)74.06K
Market Cap
$1.47M
Enterprise Value$2.17M
Total Cash (Recent Filing)$4.08K
Total Debt (Recent Filing)$133.72K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,152,520
10 Day Avg. Volume34,315
30 Day Avg. Volume74,060
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-7.14
Price to Sales (P/S)0.00
P/FCF Ratio-4.69
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioVaxys Technology News
BVAXF FAQ
What was BioVaxys Technology’s price range in the past 12 months?
BioVaxys Technology lowest stock price was $0.03 and its highest was $0.41 in the past 12 months.
What is BioVaxys Technology’s market cap?
BioVaxys Technology’s market cap is $1.47M.
When is BioVaxys Technology’s upcoming earnings report date?
BioVaxys Technology’s upcoming earnings report date is Jun 25, 2026 which is in 83 days.
How were BioVaxys Technology’s earnings last quarter?
Currently, no data Available
Is BioVaxys Technology overvalued?
According to Wall Street analysts BioVaxys Technology’s price is currently Overvalued.
Does BioVaxys Technology pay dividends?
BioVaxys Technology does not currently pay dividends.
What is BioVaxys Technology’s EPS estimate?
BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVaxys Technology have?
BioVaxys Technology has 29,152,520 shares outstanding.
What happened to BioVaxys Technology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioVaxys Technology?
Currently, no hedge funds are holding shares in BVAXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioVaxys Technology
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Vaxil Bio
―
Defence Therapeutics
―
Ownership Overview
Options Prices
Currently, No data available
---